RayKnowChina Research Map
Shortlist

Anhui Provincial Cancer Hospital

Listed for 2 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Anhui Provincial Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Lung cancer肺癌0 papers led7 open trials led
  2. Breast cancer乳腺癌0 papers led2 open trials led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Lung cancer

肺癌

Led no English-language PubMed papers on lung cancer in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
0
led by another institution

251 hospitals in China for lung cancer

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
    Phase
    Phase 4
    Started
    2026-07
    Posted
    Registry
    NCT07744698

    Age 18 years to 75 years (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  2. Recruiting
    Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06838208

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  3. Recruiting
    To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07195084

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  4. Recruiting
    QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07330596

    Age 18 years to 75 years (registered criteria)

    Led by Anhui Provincial Cancer Hospital

  5. Recruiting
    Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06714708

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  6. Not yet recruiting
    Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07627321

    Age 18 years to 75 years (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  7. Not yet recruiting
    A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07661173

    Age 18 years to Not stated (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led no English-language PubMed papers on breast cancer in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution

219 hospitals in China for breast cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07623226

    Age 18 years to 75 years; women only (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  2. Not yet recruiting
    SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07047443

    Age 18 years to 75 years; women only (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  3. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

Anhui Provincial Cancer Hospital

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data